Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research
PR Newswire
FREMONT, Calif., Oct. 7, 2022
In Japan, Colorectal Cancer (CRC) has been found out to occupy the position of most promising indication
FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis.
According to this study, the current global PD-1/PDL-1 inhibitor market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in the PD-1/PDL-1 inhibitor market generating interest of commercial as well as academic research institutions.
The following factors are responsible for the increase in demand for PD-1/PDL-1 inhibitor:
- Increased use of pd-1/pdl-1 inhibitors in multiple sub-set of cancer indications
- Increase in PD-1/PDL-1 inhibitor based combination regimens
The detailed study is a compilation of 64 market data tables and 124 figures spread through 247 pages.
Check out the detailed table of content here:
https://bisresearch.com/requestsample?id=1357&type=toc
Analyst's Take on the Market Projection
According to Tausif Qudsi, Principal Analyst – BIS Research, "PD-1/PDL-1 inhibitors are going to make a significant impact in the cancer immunotherapy segment and also indicated to modify the conventional treatment practices in coming years due to its favorable therapeutic effects on overall survival and quality of life. More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
Request a FREE sample of this report here:
https://bisresearch.com/requestsample?id=1357&type=download
Existing Competitive Landscape
The companies that are profiled have been selected based on primary research inputs gathered from a network of industry experts and analyzing company coverage, product portfolio, and market penetration.
Some of the prominent established names in this market are GlaxoSmithKline plc, Bristol-Myers Squibb Company, Arcus Biosciences, Inc., Agenus Inc., F. Hoffmann-La Roche Ltd, Astra Zeneca PLC, Beigene Ltd., Shanghai Junshi Bioscience Co. Ltd., Shanghai Henlius Biotech, Inc., Jiangsu HengRui Medicine Co., Ltd., Lee's Pharmaceutical Limited, Incyte Corporation, Biocad, CStone Pharmaceuticals, and more.
Recent Developments in the Global PD-1/PDL-1 Inhibitor Market
- In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
- In September 2022, AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
The Market Now Have Seven Approved Products Available Commercially
Among the commercially available products, four are PD-1 inhibitors, and three are PDL-1 inhibitors. Keytruda (PD-1 inhibitor) is the current market leader with $17.18 billion of reported sales for the year 2021, followed by another PD-1 inhibitor, Opdivo, with reported sales of $7.52 billion.
Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
Jemperli is the latest entrant (approved in 2021), with a reported sale of $5.9 million in 2021. Jemperli has demonstrated an excellent result of complete cure in colorectal cancer patients as a neoadjuvant treatment.
Additionally, existing products are being investigated for their therapeutic effects in combination with treatment options.
Why Should You Buy The Report?
This exclusive report on the global pd-1/pdl-1 inhibitors market will help in the following ways:
- Aids in product development
- Helps in targeting a segment for launching a new product
- Offers go to market strategies for different source types
- Pipeline analysis and competitive landscaping of key players
- Supports in analyzing the competitors' portfolio
- Partnership landscaping
Want to learn more about latest trends in advanced materials and chemicals? Speak to our analysts
Exclusive DeepTechTM MAP Analysis For Helathcare by BIS Research:
Global PD-1/PD-L1 Immunotherapy Market
About BIS Research:
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.
Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.
Contact:
Bhavya Banga
Email: media@bisresearch.com
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
1-510-404-8135
+91 – 9560375748
Dronacharya Dave
Visit our Blog @ https://bisresearch.com/news
Get Expert Insights @ https://community.insightmonk.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch
View original content:SOURCE BIS Research
